(VIANEWS) – Mobile TeleSystems OJSC (MBT), ZoomInfo (ZI), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Mobile TeleSystems OJSC (MBT)

7963.7% sales growth and 269.8% return on equity

Mobile TeleSystems Public Joint Stock Company offers telecommunication services in Russia.

Mobile TeleSystems OJSC’s sales growth this year is anticipated to be 7827.9% and 6% for next year.

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 534.4B for the twelve trailing months.

Volume

Today’s last reported volume for Mobile TeleSystems OJSC is 1 which is 100% below its average volume of 3193670.

Mobile TeleSystems OJSC’s sales growth for the next quarter is 7963.7%. The company’s growth estimates for the current quarter and the next is 6685% and 8504%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 269.8%.

Mobile TeleSystems OJSC’s Stock Yearly Top and Bottom Value

Mobile TeleSystems OJSC’s stock is valued at $5.50 at 01:22 EST, way under its 52-week high of $10.07 and higher than its 52-week low of $5.34.

Mobile TeleSystems OJSC’s Moving Average

Mobile TeleSystems OJSC’s worth is way under its 50-day moving average of $7.09 and way under its 200-day moving average of $8.49.

2. ZoomInfo (ZI)

39.8% sales growth and 4.28% return on equity

ZoomInfo Technologies Inc. provides cloud-based, go-to market intelligence platforms for marketing and sales teams across the United States as well as internationally.

ZoomInfo’s sales growth this year is anticipated to be 48.2% and 31.2% for next year.

Year-on-year quarterly revenue growth grew by 56.9%, now sitting on 590.4M for the twelve trailing months.

Volume

Today’s last reported volume for ZoomInfo is 1701880 which is 54.08% below its average volume of 3706480.

ZoomInfo’s sales growth for the next quarter is 39.8%. The company’s growth estimates for the current quarter and the next is 9.1% and 8.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.28%.

Volatility

ZoomInfo’s last day, last week, and last month’s current intraday variation average was 2.06%, 2.06%, and 2.74%, respectively.

ZoomInfo’s highest amplitude of average volatility was 3.85% (day), 3.85% (last week), and 5.71% (last month), respectively.

ZoomInfo’s Stock Yearly Top and Bottom Value

ZoomInfo’s stock is valued at $0.00 at 01:22 EST, below its 52-week low of $37.86.

ZoomInfo’s Moving Average

ZoomInfo’s value is under its 50-day moving average of $68.03 and under its 200-day moving average of $56.79.

Previous days news about ZoomInfo(ZI)

  • According to Bloomberg Quint on Sunday, 27 March, "Some market participants point to a particularly messy block trade on Monday Aug. 9, when a group of investors tapped Morgan Stanley to unload shares of ZoomInfo Technologies Inc. The group had selected Morgan Stanley for another ZoomInfo trade days earlier with satisfactory results."

3. Vertex Pharmaceuticals (VRTX)

21.3% sales growth and 24.64% return on equity

Vertex Pharmaceuticals Incorporated is involved in the development and marketing of therapies to treat cystic fibrosis.

Vertex Pharmaceuticals’s sales growth this year is anticipated to be 20.8% and 9.4% for next year.

Year-on-year quarterly revenue growth grew by 29%, now sitting on 7.13B for the twelve trailing months.

Volume

Today’s last reported volume for Vertex Pharmaceuticals is 1226550 which is 26.27% below its average volume of 1663740.

Vertex Pharmaceuticals’s sales growth for the next quarter is 21.3%. The company’s growth estimates for the ongoing quarter and the next is 31.5% and 11.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.64%.

Volatility

Vertex Pharmaceuticals’s last day, last week, and last month’s current intraday variation average was 2.30%, 1.26%, and 1.00%, respectively.

Vertex Pharmaceuticals’s highest amplitude of average volatility was 4.81% (day), 3.49% (last week), and 2.52% (last month), respectively.

Vertex Pharmaceuticals’s Stock Yearly Top and Bottom Value

Vertex Pharmaceuticals’s stock is valued at $253.95 at 01:22 EST, under its 52-week high of $254.93 and way higher than its 52-week low of $176.36.

Vertex Pharmaceuticals’s Moving Average

Vertex Pharmaceuticals’s value is above its 50-day moving average of $237.95 and way above its 200-day moving average of $206.55.

4. MVB Financial Corp. (MVBF)

20.9% sales growth and 15.03% return on equity

MVB Financial Corp. and its subsidiaries offer banking and mortgage services to Americans and corporations.

MVB Financial Corp.’s sales growth this year is anticipated to be 19.9% and 27.7% for next year.

Year-on-year quarterly revenue growth grew by 36%, now sitting on 135.25M for the twelve trailing months.

Volume

Today’s last reported volume for MVB Financial Corp. is 608 which is 97.13% below its average volume of 21244.

MVB Financial Corp.’s sales growth for the next quarter is 20.9%. The company’s growth estimates for the present quarter and the next is a negative 53% and negative -28.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.03%.

Volatility

MVB Financial Corp.’s last day, last week, and last month’s current intraday variation average was 1.22%, 1.48%, and 1.46%, respectively.

MVB Financial Corp.’s highest amplitude of average volatility was 0.85% (day), 2.64% (last week), and 2.41% (last month), respectively.

MVB Financial Corp.’s Stock Yearly Top and Bottom Value

MVB Financial Corp.’s stock is valued at $40.59 at 01:22 EST, way under its 52-week high of $45.94 and way above its 52-week low of $31.90.

MVB Financial Corp.’s Moving Average

MVB Financial Corp.’s worth is above its 50-day moving average of $39.79 and below its 200-day moving average of $41.21.

5. PacWest Bancorp (PACW)

17.3% sales growth and 15.98% return on equity

PacWest Bancorp is the bank holding company of Pacific Western Bank, which provides a variety of banking products and related services.

PacWest Bancorp’s sales growth this year is expected to be 12.2% and 9.2% for next year.

Year-on-year quarterly revenue growth grew by 25.9%, now sitting on 1.46B for the twelve trailing months.

Volume

Today’s last reported volume for PacWest Bancorp is 2132490 which is 121.53% above its average volume of 962617.

PacWest Bancorp’s sales growth for the next quarter is 17.3%. The company’s growth estimates for the current quarter and the next is a negative 18.1% and negative -28.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.98%.

Volatility

PacWest Bancorp’s last day, last week, and last month’s current intraday variation average was 0.49%, 1.52%, and 2.59%, respectively.

PacWest Bancorp’s highest amplitude of average volatility was 3.08% (day), 3.49% (last week), and 4.42% (last month), respectively.

PacWest Bancorp’s Stock Yearly Top and Bottom Value

PacWest Bancorp’s stock is valued at $44.85 at 01:22 EST, way under its 52-week high of $51.81 and way higher than its 52-week low of $35.71.

PacWest Bancorp’s Moving Average

PacWest Bancorp’s value is under its 50-day moving average of $47.61 and under its 200-day moving average of $44.86.

6. Illumina (ILMN)

15.3% sales growth and 11.86% return on equity

Illumina, Inc. offers array-based and sequencing solutions for genomic and genetic analysis.

Illumina’s sales growth this year is expected to be 36.5% and 10.6% for next year.

Year-on-year quarterly revenue growth grew by 39.5%, now sitting on 4.28B for the twelve trailing months.

Volume

Today’s last reported volume for Illumina is 479522 which is 50.8% below its average volume of 974708.

Illumina’s sales growth for the next quarter is 15.3%. The company’s growth estimates for the present quarter and the next is a negative 63.9% and negative -50.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.

Volatility

Illumina’s last day, last week, and last month’s current intraday variation average was 1.57%, 1.09%, and 2.07%, respectively.

Illumina’s highest amplitude of average volatility was 3.12% (day), 3.26% (last week), and 3.63% (last month), respectively.

Illumina’s Stock Yearly Top and Bottom Value

Illumina’s stock is valued at $341.72 at 01:22 EST, way below its 52-week high of $526.00 and way higher than its 52-week low of $302.79.

Illumina’s Moving Average

Illumina’s worth is higher than its 50-day moving average of $341.05 and way below its 200-day moving average of $408.97.

7. Deluxe Corporation (DLX)

13.2% sales growth and 11.54% return on equity

Deluxe Corporation offers technology-enabled services to small business and financial institutions throughout the United States, Canada and Australia.

Deluxe Corporation’s sales growth this year is anticipated to be 8.6% and 2.5% for next year.

Year-on-year quarterly revenue growth grew by 25.5%, now sitting on 2.02B for the twelve trailing months.

Volume

Today’s last reported volume for Deluxe Corporation is 241794 which is 5.79% above its average volume of 228558.

Deluxe Corporation’s sales growth for the next quarter is 13.2%. The company’s growth estimates for the ongoing quarter and the next is a negative 11.9% and negative -3.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.54%.

Deluxe Corporation’s Stock Yearly Top and Bottom Value

Deluxe Corporation’s stock is valued at $32.14 at 01:22 EST, way below its 52-week high of $48.38 and way above its 52-week low of $28.08.

Deluxe Corporation’s Moving Average

Deluxe Corporation’s value is above its 50-day moving average of $31.29 and way under its 200-day moving average of $36.61.

8. NICE Ltd (NICE)

8% sales growth and 7.54% return on equity

NICE Ltd.

NICE Ltd’s sales growth this year is anticipated to be 15% and 10% for next year.

Year-on-year quarterly revenue growth grew by 19.7%, now sitting on 1.84B for the twelve trailing months.

Volume

Today’s last reported volume for NICE Ltd is 133631 which is 53.12% below its average volume of 285091.

NICE Ltd’s sales growth for the next quarter is 8%. The company’s growth estimates for the current quarter and the next is 5.6% and 10.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.54%.

Volatility

NICE Ltd’s last day, last week, and last month’s current intraday variation average was 3.15%, 3.78%, and 2.54%, respectively.

NICE Ltd’s highest amplitude of average volatility was 4.91% (day), 4.18% (last week), and 4.25% (last month), respectively.

NICE Ltd’s Stock Yearly Top and Bottom Value

NICE Ltd’s stock is valued at $217.57 at 01:22 EST, way under its 52-week high of $319.88 and above its 52-week low of $199.32.

NICE Ltd’s Moving Average

NICE Ltd’s worth is below its 50-day moving average of $237.58 and way under its 200-day moving average of $268.16.

LEAVE A REPLY

Please enter your comment!
Please enter your name here